Ten kHz spinal cord stimulation for the treatment of chronic peripheral polyneuropathy: 12-Month results from prospective open-label pilot study

被引:8
作者
Galan, Vincent [1 ]
Scowcroft, James [2 ]
Chang, Paul [1 ]
Li, Sean [3 ]
Staats, Peter [3 ]
Subbaroyan, Jeyakumar [4 ]
Caraway, David [4 ]
机构
[1] Georgia Pain Care, 1365 Rock Quarry Rd,Suite 202, Stockbridge, GA 30281 USA
[2] KC Pain Ctr, Lees Summit, MO USA
[3] Premier Pain Ctr, Shrewsbury, NJ USA
[4] Nevro Corp, Redwood City, CA USA
关键词
10 kHz SCS; chronic peripheral polyneuropathy; visual analog scale; QUALITY-OF-LIFE; 10-KHZ HIGH-FREQUENCY; CHRONIC PAIN; CHRONIC BACK; NEUROPATHY; OUTCOMES; EFFICACY; LIMB; SCS; MULTICENTER;
D O I
10.1111/papr.13059
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background The goal of this study was to demonstrate that the paresthesia-independent 10 kHz spinal cord stimulation (SCS) can provide long-term pain relief in patients with peripheral polyneuropathy (PPN). Clinically diagnosed subjects with PPN refractory to conventional medical management were enrolled in this prospective, multicenter study between November 2015 and August 2016, after institutional review board approval and patient informed consent were obtained. Methods Subjects underwent trial stimulation utilizing 2 epidural leads, and if successful, were implanted with a permanent 10 kHz SCS system and followed up for 12 months post-implant. Outcome measures included adverse events, pain, neurological assessments, disability, function, quality of life, pain interference, sleep, satisfaction, and global impression of change. Data are presented as descriptive statistics. Permanent implant population results are reported as mean +/- standard error. Results Twenty-one of the 26 trialed subjects had a successful trial and 18 received a permanent implant. All subjects had the leads placed anatomically without the need for paresthesia. Subjects experienced significant and sustained pain relief (at least 65% at all timepoints) whereas physicians noted improvements in neurological function. Significant improvements in disability, function, sleep, sensory, and affective dimensions of pain were reported at all timepoints. All adverse events were resolved without sequelae. Conclusion Findings from this study suggest that 10 kHz SCS may provide sustained pain relief and disability improvements in patients suffering from PPN.
引用
收藏
页码:898 / 906
页数:9
相关论文
共 47 条
  • [41] Conventional vs. pulsed-light accelerated corneal collagen cross-linking for the treatment of progressive keratoconus: 12-month results from a prospective study
    Jiang, Liang-Zhu
    Jiang, Wei
    Qiu, Shi-Yan
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (05) : 4238 - 4244
  • [42] Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients
    Moberly, James B.
    Ford, Daniel M.
    Zahir, Hamim
    Chen, Shuquan
    Mochizuki, Takashi
    Truitt, Kenneth E.
    Vollmer, Timothy L.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2012, 246 (1-2) : 100 - 107
  • [43] Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Rudwaleit, M.
    Mazurov, V. I.
    Myasoutova, L.
    Park, S.
    Song, Y.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 108 - 113
  • [44] Surgical treatment of refractory low back pain using implanted BurstDR spinal cord stimulation (SCS) in a cohort of patients without options for corrective surgery: Findings and results from the DISTINCT study, a prospective randomized multi-center-controlled trial
    Yue, James J.
    Gilligan, Christopher J.
    Falowski, Steven
    Jameson, Jessica
    Desai, Mehul J.
    Moeschler, Susan
    Pilitsis, Julie
    Heros, Robert
    Tavel, Edward
    Wahezi, Sayed
    Funk, Robert
    Buchanan, Patrick
    Christopher, Anne
    Weisbein, Jacqueline
    Patterson, Denis
    Levy, Robert
    Antony, Ajay
    Miller, Nathan
    Scarfo, Keith
    Kreiner, Scott
    Wilson, Derron
    Lim, Chi
    Braun, Edward
    Dickerson, David
    Duncan, Jonathan
    Xu, Jijun
    Candido, Kenneth
    Mohab, Ibrahim
    Michael, Fishell
    Blomme, Bram
    Okaro, Udoka
    Deer, Timothy
    [J]. NORTH AMERICAN SPINE SOCIETY JOURNAL, 2024, 19
  • [45] Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension
    Takeda, Masayuki
    Nishizawa, Osamu
    Imaoka, Takeshi
    Morisaki, Yoji
    Viktrup, Lars
    [J]. LUTS-LOWER URINARY TRACT SYMPTOMS, 2012, 4 (03) : 110 - 119
  • [46] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [47] Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
    Hurvitz, Sara A.
    Bosserman, Linda D.
    Chan, David
    Hagenstad, Christopher T.
    Kass, Frederick C.
    Smith, Frederick P.
    Rodriguez, Gladys I.
    Childs, Barrett H.
    Slamon, Dennis J.
    [J]. SPRINGERPLUS, 2014, 3 : 1 - 9